InsiderSignal.AI

InsiderSignal.ai

CYTK - Cytokinetics Inc

Insider Sale by Callos Andrew (EVP, Chief Commercial Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

Yesterday, Callos Andrew, serving as EVP, Chief Commercial Officer at Cytokinetics Inc (CYTK), sold 15,000 shares at $63.26 per share, for a total transaction value of $948,900.00. Following this transaction, Callos Andrew now holds 58,555 shares of CYTK.

This sale represents a 20.00% decrease in Callos Andrew's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, April 30, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 30, 2026, meaning the disclosure happened on the same day as the trade.

Cytokinetics Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Callos Andrew

Callos Andrew

EVP, Chief Commercial Officer

# Andrew Callos Andrew Callos is the Executive Vice President and Chief Commercial Officer at Cytokinetics Incorporated (CYTK), a position he has held since joining the company in March 2021.[[1]](https://cytokinetics.com/company/senior-management/team-member/andrew-callos/)[[2]](https://www.zippia.com/cytokinetics-careers-3201/executives/)[[3]](https://www.gurufocus.com/insider/168129/andrew-callos)[[5]](https://cytokinetics.com/company/senior-management/) Based in the San Francisco Bay Area and Philadelphia, he oversees commercial operations for the biopharmaceutical firm.[[2]](https://www.zippia.com/cytokinetics-careers-3201/executives/)[[4]](https://www.zoominfo.com/p/Andrew-Callos/9560207491) Callos brings over 20 years of experience in biopharma, including more than 11 years at Pfizer, where he served as Regional President and General Manager, North America, Upjohn Business Unit, Vice President U.S. Cardiology & Metabolic Marketing (leading the U.S. commercialization of Eliquis), Vice President and Head of Inflammation Marketing Europe, and Vice President Global Commercial Development Rare Disease.[[1]](https://cytokinetics.com/company/senior-management/team-member/andrew-callos/)[[2]](https://www.zippia.com/cytokinetics-careers-3201/executives/) Prior to Pfizer, he spent over 10 years at Wyeth Pharmaceuticals in roles such as AVP Marketing for products including Effexor and oral contraceptives, and began his career as a Consulting Manager at Accenture for seven years.[[1]](https://cytokinetics.com/company/senior-management/team-member/andrew-callos/)[[2]](https://www.zippia.com/cytokinetics-careers-3201/executives/) He holds a B.S. in Commerce and Engineering from Drexel University.[[1]](https://cytokinetics.com/company/senior-management/team-member/andrew-callos/) As a corporate insider, Callos has engaged in recent stock transactions at Cytokinetics.[[3]](https://www.gurufocus.com/insider/168129/andrew-callos)[[6]](https://www.investing.com/news/insider-trading-news/cytokinetics-evp-callos-andrew-sells-shares-for-117-million-93CH-3928167)

View full insider profile →

Trade Price

$63.26

Quantity

15,000

Total Value

$948,900.00

Shares Owned

58,555

Trade Date

Thursday, April 30, 2026

1 days ago

SEC Filing Date

Thursday, April 30, 2026

HEALTHCAREBIOTECHNOLOGY

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning CYTK

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/6080159

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime